0000000000267296

AUTHOR

Nuria Muelas

showing 8 related works from this author

Plectin-related scapuloperoneal myopathy with treatment-responsive myasthenic syndrome

2020

AdultMalePathologymedicine.medical_specialtyHistologymyasthenic syndromeMuskel- und KnochenstoffwechselPathology and Forensic MedicineEpidermolysis bullosa simplexAdrenergic AgentsPhysiology (medical)medicineHumansMuscular dystrophyFrameshift MutationEphedrineMyasthenic Syndromes Congenitalbusiness.industryPlectin-relatedPlectinmedicine.diseaseScapuloperoneal myopathyMuscular Dystrophy Emery-Dreifusstreatment-responsiveNeurologyPlectinNeurology (clinical)business
researchProduct

Mutations in theMORC2gene cause axonal Charcot–Marie–Tooth disease

2015

Charcot-Marie-Tooth disease (CMT) is a complex disorder with wide genetic heterogeneity. Here we present a new axonal Charcot-Marie-Tooth disease form, associated with the gene microrchidia family CW-type zinc finger 2 (MORC2). Whole-exome sequencing in a family with autosomal dominant segregation identified the novel MORC2 p.R190W change in four patients. Further mutational screening in our axonal Charcot-Marie-Tooth disease clinical series detected two additional sporadic cases, one patient who also carried the same MORC2 p.R190W mutation and another patient that harboured a MORC2 p.S25L mutation. Genetic and in silico studies strongly supported the pathogenicity of these sequence variant…

AdultMale0301 basic medicinePathologymedicine.medical_specialtyGene ExpressionSchwann cellSural nerveBiologyFasciculationMiceYoung Adult03 medical and health sciences0302 clinical medicineAtrophySural NerveCharcot-Marie-Tooth DiseasemedicineAnimalsHumansAxonAgedGenetic heterogeneityInfantSensory lossMiddle Agedmedicine.diseaseSciatic NerveAxonsPedigreePhenotype030104 developmental biologymedicine.anatomical_structureMutationFemaleNeurology (clinical)Myokymiamedicine.symptomNeuroscience030217 neurology & neurosurgeryTranscription FactorsBrain
researchProduct

Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy

2021

ABSTRACTObjectiveTo assess in adult spinal muscular atrophy (SMA) patients the construct validity and responsiveness of several outcome measures.MethodsPatients older than 15 years and followed-up at least for 6 months, between October 2015 and August 2020, with one motor function scale (Hammersmith Functional Motor Scale Expanded, HFMSE; Revised Upper Limb module, RULM) in five referral centers were included. Bedside functional scales (Egen Klassification, EK2; Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, ALSFRS-R) were also collected when available. Correlations and regression models were performed to evaluate the construct validity. The monthly slopes of change were use…

medicine.medical_specialtybusiness.industryConstruct validityRegression analysisSpinal muscular atrophymedicine.diseaseSMA*Physical medicine and rehabilitationmedicine.anatomical_structureRating scaleFloor effectmedicineUpper limbAmyotrophic lateral sclerosisbusiness
researchProduct

Charcot-Marie-Tooth disease: Genetic and clinical spectrum in a Spanish clinical series

2013

Objectives: To determine the genetic distribution and the phenotypic correlation of an extensive series of patients with Charcot-Marie-Tooth disease in a geographically well-defined Mediterranean area. Methods: A thorough genetic screening, including most of the known genes involved in this disease, was performed and analyzed in this longitudinal descriptive study. Clinical data were analyzed and compared among the genetic subgroups. Results: Molecular diagnosis was accomplished in 365 of 438 patients (83.3%), with a higher success rate in demyelinating forms of the disease. The CMT1A duplication (PMP22 gene) was the most frequent genetic diagnosis (50.4%), followed by mutations in the GJB1…

Foot DeformitiesMalecongenital hereditary and neonatal diseases and abnormalitiesPathologymedicine.medical_specialtyDNA Mutational AnalysisNerve Tissue ProteinsDiseaseArticleConnexinsCentral nervous system diseaseDegenerative diseasestomatognathic systemCharcot-Marie-Tooth DiseaseGene duplicationHumansMedicineLongitudinal StudiesMuscle StrengthGeneRetrospective StudiesGeneticsSeries (stratigraphy)business.industryRetrospective cohort studymedicine.diseasePhenotypeMuscular Atrophystomatognathic diseasesSpainMutationSensation DisordersFemaleNeurology (clinical)businessMyelin ProteinsNeurology
researchProduct

A Roma founder BIN1 mutation causes a novel phenotype of centronuclear myopathy with rigid spine

2018

ObjectiveTo describe a large series of BIN1 patients, in which a novel founder mutation in the Roma population of southern Spain has been identified.MethodsPatients diagnosed with centronuclear myopathy (CNM) at 5 major reference centers for neuromuscular disease in Spain (n = 53) were screened for BIN1 mutations. Clinical, histologic, radiologic, and genetic features were analyzed.ResultsEighteen patients from 13 families carried the p.Arg234Cys variant; 16 of them were homozygous for it and 2 had compound heterozygous p.Arg234Cys/p.Arg145Cys mutations. Both BIN1 variants have only been identified in Roma, causing 100% of CNM in this ethnic group in our cohort. The haplotype analysis confi…

Adult0301 basic medicinemedicine.medical_specialtyRomaNeuromuscular diseaseAdolescentPopulationMallory BodiesCompound heterozygosityArticleMuscular DystrophiesCohort StudiesYoung Adult03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansProspective StudiesCentronuclear myopathyChildeducationProspective cohort studyAdaptor Proteins Signal TransducingRetrospective Studieseducation.field_of_studybusiness.industryTumor Suppressor ProteinsHaplotypeNuclear ProteinsRetrospective cohort studyMiddle Agedmedicine.diseaseFounder EffectPhenotype030104 developmental biologyScoliosisSpainMutation[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Neurology (clinical)business030217 neurology & neurosurgeryMyopathies Structural CongenitalFounder effect
researchProduct

Nusinersen in adult patients with 5q spinal muscular atrophy: a multicenter observational cohorts’ study

2021

ABSTRACTObjectiveTo assess safety and efficacy of nusinersen in adult 5q spinal muscular atrophy (SMA) patients.MethodsPatients older than 15 years and followed at least for 6 months with one motor scale (Hammersmith Functional Motor Scale Expanded, HFMSE; Revised Upper Limb module, RULM) in five referral centers were included. Clinical and patients’ global impression of change (CGI-C and PGI-C) were recorded in treated patients at the last visit. Functional scales (Egen Klassification, EK2; Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, ALSFRS-R) and the percent-predicted forced vital capacity were collected when available.ResultsSeventy-nine SMA patients (39 treated with n…

Vital capacitymedicine.medical_specialtybusiness.industrySpinal muscular atrophySMA*medicine.diseasemedicine.anatomical_structureRating scaleInternal medicinemedicineUpper limbNusinersenAmyotrophic lateral sclerosisbusinessAdverse effect
researchProduct

Clinical and genetic characteristics of 21 Spanish patients with biallelic pathogenic SPG7 mutations.

2021

Spastic paraplegia type 7 (SPG7) is one of the most common hereditary spastic paraplegias. SPG7 mutations most often lead to spastic paraparesis (HSP) and/or hereditary cerebellar ataxia (HCA), frequently with mixed phenotypes. We sought to clinically and genetically characterize a Spanish cohort of SPG7 patients. Patients were recruited from our HCA and HSP cohorts. We identified twenty-one patients with biallelic pathogenic SPG7 mutations. Mean age at onset was 37.4 years (SD ± 14.3). The most frequent phenotype was spastic ataxia (57%), followed by pure spastic paraplegia (19%) and complex phenotypes (19%). Isolated patients presented with focal or multifocal dystonia, subclinical myopat…

medicine.medical_specialtyNeurogeneticsCompound heterozygosityGastroenterologyInternal medicinemedicineSpasticHumansMyopathySubclinical infectionDystoniaCerebellar ataxiabusiness.industrySpastic Paraplegia HereditaryMetalloendopeptidasesmedicine.diseasenervous system diseasesOptic AtrophyPhenotypeNeurologyMutationATPases Associated with Diverse Cellular ActivitiesNeurology (clinical)medicine.symptombusinessSpastic paraplegia type 7Journal of the neurological sciences
researchProduct

Infections of the Central Nervous System after Unrelated Donor Umbilical Cord Blood Transplantation or Human Leukocyte Antigen–Matched Sibling Transp…

2016

We analyzed the incidence, clinical characteristics, prognostic factors, and outcome of central nervous system (CNS) infections in consecutive patients with receiving umbilical cord blood transplantation (UCBT) (n = 343) or HLA-matched sibling donor stem cell transplantation (MST) (n = 366). Thirty-four CNS infections were documented at a median time of 116 days after transplantation (range, 7 to 1161). The cumulative incidence (CI) risk of developing a CNS infection was .6% at day +30, 2.3% at day +90, and 4.9% at 5 years. The 5-year CI of CNS infection was 8.2% after UCBT and 1.7% after MST (P  .001). The causative micro-organisms of CNS infections were fungi (35%), virus (32%), Toxoplasm…

Adultmedicine.medical_specialtyTime FactorsAdolescentCentral nervous systemHuman leukocyte antigenGastroenterologyYoung Adult03 medical and health sciencesCentral Nervous System Infections0302 clinical medicineHLA AntigensInternal medicinemedicineHumansCumulative incidenceAgedTransplantationbusiness.industryUmbilical Cord Blood TransplantationIncidenceSiblingsIncidence (epidemiology)Hematopoietic Stem Cell TransplantationBacterial InfectionsHematologyMiddle Agedmedicine.diseaseTransplantationmedicine.anatomical_structureMycosesVirus DiseasesHistocompatibility030220 oncology & carcinogenesisImmunologyCord Blood Stem Cell TransplantationStem cellUnrelated DonorsbusinessToxoplasmosisEncephalitis030215 immunologyBiology of Blood and Marrow Transplantation
researchProduct